via Genentech
Patients with age-related macular degeneration may soon see their monthly injection become an annual refill, with potentially better results
A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months in between treatments. This represents a vast improvement over the typical regimen of nearly monthly eye injections. The researchers involved in the Phase II clinical study say the implant is not just about convenience; a more consistent treatment will also help people keep more of their vision. They are presenting their research today at AAO 2018, the 122nd Annual Meeting of the American Academy of Ophthalmology.
A lead researcher from Wills Eye Hospital in Philadelphia is presenting results from the LADDER study evaluating the efficacy and safety of an investigational, long-acting port delivery system for Lucentis (ranibizumab), a drug that improves vision for millions across the globe suffering from age-related macular degeneration.
The multicenter, randomized trial included 220 patients. The study determined the time until a patient needed a refill of the implant. It also evaluated the effectiveness of three different concentrations of Lucentis compared with monthly injections of the drug.
Before Lucentis was introduced 12 years ago, people with wet AMD were almost certain to develop severe vision loss or blindness. Lucentis was the first treatment to slow the disease, allowing more than 90 percent of patients to keep their vision, according to clinical trials. However, in the real world, the percentage is closer to 50 percent. One of the main reasons why is that patients are undertreated. This is because most people with AMD must go to the ophthalmologist’s office every six to eight weeks to keep their vision. This can be a difficult schedule to maintain for many elderly patients struggling with other maladies and reliant on others to get them to their ophthalmologist visits.
Researchers have been searching for a better alternative to monthly injections almost from the moment Lucentis was introduced. One of the latest ideas is to surgically implant a refillable drug reservoir device, slightly longer than a grain of rice, into the eye. Filled with a concentrated version of Lucentis, the device, called the port delivery system, delivers drug to the back of the eye over a longer time frame.
Lead site investigator, Carl D. Regillo, M.D., chief of retina service and professor of Ophthalmology at Wills Eye Hospital, said that patients treated with the highest drug concentration were able to go a median of 15 months before needing a refill. Port delivery treatment was also as effective as monthly injections.
“Fewer injections and office visits is exciting,” said Dr. Regillo, who administers more than 100 injections a week. “But more importantly, we think it will translate into better visual outcomes because in the real world, patients get less treatment than they need. It’s not done consciously. Over time, things happen: illness, hospitalization, a snowstorm, etc. and appointments are missed or delayed. If you’re a week or two late for a visit from time to time, you may have a decline in vision, and you can’t always recover from that. It’s a relentlessly progressive disease.”
The study did find some side effects from surgery, but the overall safety profile was good. The device is not visible on the outside of the eye. It’s implanted under the eyelid, appearing, at most, as a tiny dot. After the initial surgery, it can be refilled during an office visit.
Dr. Regillo anticipates that the new delivery system could be available to patients in about three years.
Learn more:Â Easier treatment for blinding eye disease shows promise in clinical trial
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Scientists Discover Genetic Clues Related to Treating Macular Degenerationon July 28, 2022 at 12:30 pm
Better treatments for an eye condition that can cause blindness are a major step closer after scientists discovered genetic clues that show who has it. Researchers in Australia have unearthed genetic ...
- Molecular Signatures of Age-Related Macular Degeneration Identifiedon July 27, 2022 at 2:10 am
The discovery of molecular signatures of the incurable eye disease, age-related macular degeneration, could improve diagnosis and treatment.
- Clues to age-related macular degeneration revealedon July 26, 2022 at 12:51 pm
Better diagnosis and treatment of the incurable eye disease age-related macular degeneration is a step closer, thanks to the discovery of new genetic signatures of the disease.
- Macular Degeneration Molecular Signature May Aid Diagnosis, Treatmenton July 26, 2022 at 5:00 am
The discovery of molecular signatures of age-related macular degeneration aid diagnosis and treatment of the progressive eye disease.
- Better Diagnosis and Treatment: Genetic Clues to Age-Related Macular Degenerationon July 26, 2022 at 2:01 am
The discovery of molecular signatures of age-related macular degeneration will help with better diagnosis and treatment of this progressive eye disease. Thanks to the discovery of new genetic ...
- Genetic clues to age-related macular degeneration revealedon July 26, 2022 at 2:00 am
Better diagnosis and treatment of the incurable eye disease age-related macular degeneration is a step closer, thanks to the discovery of new genetic signatures of the disease.
- Age-related Macular Degeneration (AMD) Market Research Report 2022on July 26, 2022 at 1:58 am
The "Age-related Macular Degeneration (AMD) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This 'Age-related Macular ...
- Faricimab reduces treatment burden of neovascular age-related macular degeneration: Lanceton July 20, 2022 at 7:30 am
A new study published in The Lancet suggests that Faricimab can effectively prolong the duration between treatments with continued efficacy and reduce treatment burden in patients with ...
- Macular Degeneration Explained: Causes, Symptoms, And Treatmentson July 20, 2022 at 6:56 am
Many conditions can cause vision loss or even blindness, and age-related macular degeneration (AMD) is one of the most common. Here's what we know about it.
via Bing News